Scheinman Sarah B, Sugasini Dhavamani, Zayed Monay, Yalagala Poorna C R, Marottoli Felecia M, Subbaiah Papasani V, Tai Leon M
Department of Anatomy and Cell Biology, University of Illinois at Chicago, Chicago, IL, United States.
Division of Endocrinology and Metabolism, Department of Medicine, University of Illinois at Chicago, Chicago, IL, United States.
Front Neurosci. 2021 Jul 1;15:690410. doi: 10.3389/fnins.2021.690410. eCollection 2021.
Compared with , is associated with greater age-related cognitive decline and higher risk of neurodegenerative disorders. Therefore, development of supplements that target genotype-modulated processes could provide a great benefit for the aging population. Evidence suggests a link between genotype and docosahexaenoic acid (DHA); however, clinical studies with current DHA supplements have produced negative results in dementia. The lack of beneficial effects with current DHA supplements may be related to limited bioavailability, as the optimal form of DHA for brain uptake is lysophosphatidylcholine (LPC)-DHA. We previously developed a method to enrich the LPC-DHA content of krill oil through lipase treatment (LT-krill oil), which resulted in fivefold higher enrichment in brain DHA levels in wild-type mice compared with untreated krill oil. Here, we evaluated the effect of a control diet, diet containing krill oil, or a diet containing LT-krill oil in - and targeted replacement mice (-TR mice; treated from 4 to 12 months of age). We found that DHA levels in the plasma and hippocampus are lower in -TR mice and that LT-krill oil increased DHA levels in the plasma and hippocampus of both - and -TR mice. In -TR mice, LT-krill oil treatment resulted in higher levels of the synaptic vesicle protein SV2A and improved performance on the novel object recognition test. In conclusion, our data demonstrate that LPC-DHA/EPA-enriched krill oil can increase brain DHA and improve memory-relevant behavior in mice that express . Therefore, long-term use of LT-krill oil supplements may on some level protect against age-related neurodegeneration.
与……相比,……与年龄相关的认知衰退程度更高以及神经退行性疾病风险更高有关。因此,开发针对……基因型调节过程的补充剂可能会给老年人群带来巨大益处。有证据表明……基因型与二十二碳六烯酸(DHA)之间存在联系;然而,目前使用DHA补充剂的临床研究在痴呆症方面产生了负面结果。目前的DHA补充剂缺乏有益效果可能与生物利用度有限有关,因为大脑摄取DHA的最佳形式是溶血磷脂酰胆碱(LPC)-DHA。我们之前开发了一种通过脂肪酶处理来提高磷虾油中LPC-DHA含量的方法(LT-磷虾油),与未处理的磷虾油相比,该方法使野生型小鼠大脑中的DHA水平提高了五倍。在这里,我们评估了对照饮食、含磷虾油的饮食或含LT-磷虾油的饮食对……和靶向替代小鼠(……-TR小鼠;从4个月到12个月龄进行处理)的影响。我们发现……-TR小鼠血浆和海马体中的DHA水平较低,并且LT-磷虾油增加了……和……-TR小鼠血浆和海马体中的DHA水平。在……-TR小鼠中,LT-磷虾油处理导致突触小泡蛋白SV2A水平升高,并改善了新物体识别测试中的表现。总之,我们的数据表明,富含LPC-DHA/EPA的磷虾油可以增加表达……的小鼠大脑中的DHA,并改善与记忆相关的行为。因此,长期使用LT-磷虾油补充剂可能在一定程度上预防与年龄相关的神经退行性变。